Chemical Engineering @ChemengFiles.Com

Any process that must be monitored sensors required to know the variables of a process in real time. If required to monitor a large number of process variables in the same proportion will require a large number of sensors for these variables. The sensors are expensive, require maintenance and may be calibrated to be very sensitive, plus they need a "hardware" that connect to the monitoring unit. Would not it be better if you could spare some few sensors and still be able to monitor the entire process?

This is the aim of so-called "virtual sensors" or "Software Sensors", better known in the control engineering as "observers" or "state estimator". Observers are computer programs from the measurements obtained by a number of real sensors, to estimate the process variables that does not have its respective sensor. The program reproduces the observed system giving you the information of what the stimuli (inputs) that receives the actual process. A second source of useful information for the observer is the data received from the monitoring system performance (outputs).

Cambridge Laboratories Limited has announced that its main product, Tetrabenazine, (known as NITOMAN (R) in Germany and other key territories in Europe and XENAZINE (R) in the UK, U.S. and other markets) has received the approval of the market in Spain through the Spanish Agency of Medicines and Health Products.

The company has also announced that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, in addition to renewing existing agreements enAustraliay New Zealand.

The FDA has approved a new drug application Investigacional (IND) of Nerviano Medical Sciences to begin a Phase I clinical trial with a selective small molecule inhibitor of PLK-1 for cancer treatment.

PLK-1 is a mitotic kinase required for the proliferation of cancer cells. This new compound is orally bioavailable, highly effective and well tolerated in preclinical models of cancer after a continuous dosage. This only adds another inhibitor promising candidate for the range of innovative cell cycle with different mechanisms of action in clinical development, which was discovered and developed by NMS. These include inhibitors of CDK, Aurora, and CDC-7. The IND for the inhibitor 7-CDC received approval from the FDA in January this year and the first patients undergoing treatment with this compound in April. NMS CDK and Aurora inhibitors are in phase I and II clinical development, respectively, and are beginning to discover its promising activity in specific patient populations.